SCHEMBL19591968

SCHEMBL19591968

CCCCN(C)C1CCN(C(C)C)CC1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 4/20 0.46
SMN1; SMN2 Q16637 1/20 0.40
UBE2M P61081 3/20 0.33
DCUN1D1 Q96GG9 3/20 0.33
JAK2 O60674 1/20 0.33
JAK1 P23458 1/20 0.33
FLT3 P36888 1/20 0.33
JAK3 P52333 1/20 0.33
SLC6A2 P23975 1/20 0.33
SLC6A4 P31645 1/20 0.33
SLC6A3 Q01959 1/20 0.33
TSHR P16473 1/20 0.32
KMT2A Q03164 1/20 0.31
TP53 P04637 1/20 0.31
PIK3CD O00329 1/20 0.31
POLB P06746 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18501245 0.90 HRH3 (0.41) HRH3SMN1; SMN2UBE2MDCUN1D1JAK2
SCHEMBL12885055 0.89 HRH3 (0.39) HRH3SMN1; SMN2SLC6A4TSHRTP53
SCHEMBL26029872 0.83 SMN1; SMN2 (0.36) HRH3SMN1; SMN2UBE2MDCUN1D1SLC6A2
SCHEMBL12026434 0.81 HRH3 (0.43) HRH3SMN1; SMN2SLC6A4TSHRTP53
SCHEMBL19939276 0.81 HRH3 (0.36) HRH3SMN1; SMN2
SCHEMBL25123177 0.81 HRH3 (0.33) HRH3SMN1; SMN2SLC6A2SLC6A4SLC6A3
SCHEMBL12030663 0.81 HRH3 (0.39) HRH3SMN1; SMN2TSHRKMT2ATP53
SCHEMBL25122586 0.80 POLB (0.33) HRH3SMN1; SMN2SLC6A2SLC6A4SLC6A3
SCHEMBL18501249 0.80 HRH3 (0.37) HRH3SMN1; SMN2
SCHEMBL23776737 0.80 EBP (0.36) HRH3SLC6A2SLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11078199-B2 Quinolone derivatives as fibroblast growth factor receptor inhibitors PRINCIPIA BIOPHARMA, INC. (US) 2021-08-03 US disclosed
US-20190233418-A1 QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS PRINCIPIA BIOPHARMA INC. 2019-08-01 US disclosed
US-10294223-B2 Quinolone derivatives as fibroblast growth factor receptor inhibitors PRINCIPIA BIOPHARMA, INC. (US) 2019-05-21 US disclosed
US-20180065960-A1 QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS PRINCIPIA BIOPHARMA INC. 2018-03-08 US disclosed
US-9815834-B2 Quinolone derivatives as fibroblast growth factor receptor inhibitors PRINCIPIA BIOPHARMA, INC. (US) 2017-11-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11078199-B2 Quinolone derivatives as fibroblast growth factor receptor inhibitors FGFR1, FGFR3, FGFR2 HRH3 1738/4885SMN1; SMN2 4245/4885UBE2M 3673/4885
US-20190233418-A1 QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS FGFR1, FGFR3, FGFR2 HRH3 1738/4885SMN1; SMN2 4245/4885UBE2M 3673/4885
US-10294223-B2 Quinolone derivatives as fibroblast growth factor receptor inhibitors FGFR1, FGFR3, FGFR2 HRH3 1738/4885SMN1; SMN2 4245/4885UBE2M 3673/4885
US-20180065960-A1 QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS FGFR1, FGFR3, FGFR2 HRH3 1738/4885SMN1; SMN2 4245/4885UBE2M 3673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.